智通财经APP获悉，2025年8月22日，沛嘉医疗有限公司(09996，以下简称“本集团”)发布了截至2025年6月30日止六个月(“报告期”)的中期业绩。报告期内，本集团实现总收入人民币3.53亿元，较2024年同期增长17.3%。收入结构保持稳定，其中经导管主动脉瓣置换(TAVR)相关产品贡献45.7%，神经介入产品贡献54.3%(2024年同期分别为43.3%和56.7%)。财务摘要：收入可...
Source Link智通财经APP获悉，2025年8月22日，沛嘉医疗有限公司(09996，以下简称“本集团”)发布了截至2025年6月30日止六个月(“报告期”)的中期业绩。报告期内，本集团实现总收入人民币3.53亿元，较2024年同期增长17.3%。收入结构保持稳定，其中经导管主动脉瓣置换(TAVR)相关产品贡献45.7%，神经介入产品贡献54.3%(2024年同期分别为43.3%和56.7%)。财务摘要：收入可...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.